BPC-157.

Quick Reference

Compound name	BPC-157 (Body Protection Compound-157)
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Amino-acid count	15 (pentadecapeptide)
Molecular formula	C62H98N16O22
Molecular weight	~1419.5 g/mol
CAS number	137525-51-0
Parent molecule	Fragment of BPC (Body Protection Compound), a protein isolated from human gastric juice
Typical format	Lyophilised powder in sealed vial; reconstituted in bacteriostatic water for laboratory work
Typical research purity	>99% by HPLC (verified batch-by-batch by Janoshik Analytical)

Background

BPC-157 is the designation given to a 15-amino-acid fragment of Body Protection Compound, a protein originally isolated from human gastric juice by Sikiric and colleagues. It was proposed in the early 1990s that this fragment retained the stability and activity attributed to the parent compound in cell-signalling research models.

Unlike many naturally occurring peptides, BPC-157 has an unusual stability profile in aqueous solution and has not required carrier molecules or lipid modifications to remain intact during in-vitro work. This has made it one of the most widely studied short peptides in the preclinical literature over the last three decades.

What the Literature Describes

The published preclinical literature characterises BPC-157 primarily in three research areas. The summary below is drawn from peer-reviewed studies; none of it constitutes a therapeutic claim for human use.

• Connective-tissue and tendon models. Rodent studies examining the behaviour of tendon-derived fibroblasts in the presence of BPC-157 form one of the most frequently cited threads in the literature.
• Gastrointestinal cell-signalling models. Given the compound's origin as a fragment of a gastric juice protein, a substantial body of work investigates its effects on intestinal epithelium and related signalling pathways in rodent models.
• Nitric oxide and vasomotor signalling. Several research groups have explored BPC-157 interactions with the NO system in preclinical cardiovascular models.

For a representative entry-point into the PubMed record, search terms such as "BPC-157 tendon", "BPC-157 gastric" and "pentadecapeptide BPC" return the core publications by Sikiric's research group and subsequent independent confirmations.

Related Research Compounds

Researchers working with BPC-157 often work alongside one or more of the following compounds in the preclinical literature:

• TB-500 (Thymosin Beta-4 fragment) - frequently studied in parallel in connective-tissue research models.
• GHK-Cu - copper-peptide complex studied in fibroblast / extracellular-matrix research.
• Thymosin Alpha-1 - fragment of prothymosin alpha studied in T-cell signalling models.
• KLOW Blend - a four-peptide research blend combining BPC-157, GHK-Cu, TB-500 and KPV in a single lyophilised vial.

Compare BPC-157 with Related Compounds

• Compare BPC-157 vs TB-500 - side-by-side mechanism, pricing and lab handling.

Key Literature References

• Sikiric P et al. Stable gastric pentadecapeptide BPC 157 - preclinical reviews. (PMID: 29360469) →

References are independent peer-reviewed sources. Black & White Peptides Ltd is not affiliated with these publications.